JP2018529739A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018529739A5 JP2018529739A5 JP2018517345A JP2018517345A JP2018529739A5 JP 2018529739 A5 JP2018529739 A5 JP 2018529739A5 JP 2018517345 A JP2018517345 A JP 2018517345A JP 2018517345 A JP2018517345 A JP 2018517345A JP 2018529739 A5 JP2018529739 A5 JP 2018529739A5
- Authority
- JP
- Japan
- Prior art keywords
- alkylene
- aryl
- cycloalkyl
- compound
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000003118 aryl group Chemical group 0.000 claims 11
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 5
- -1 oxaziridinyl Chemical group 0.000 claims 5
- 125000004104 aryloxy group Chemical group 0.000 claims 4
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 125000005275 alkylenearyl group Chemical group 0.000 claims 2
- 125000005218 alkyleneheteroaryl group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- LLSRLLPHUVVLQJ-UHFFFAOYSA-N 1-cycloheptyldiazepane Chemical compound C1CCCCCC1N1NCCCCC1 LLSRLLPHUVVLQJ-UHFFFAOYSA-N 0.000 claims 1
- KVTUSMPNLUCCQO-UHFFFAOYSA-N 3,3-difluoropyrrolidine Chemical compound FC1(F)CCNC1 KVTUSMPNLUCCQO-UHFFFAOYSA-N 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000004069 aziridinyl group Chemical group 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000004802 cyanophenyl group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000005959 diazepanyl group Chemical group 0.000 claims 1
- 125000004212 difluorophenyl group Chemical group 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000000160 oxazolidinyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000003367 polycyclic group Chemical group 0.000 claims 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
- 125000001984 thiazolidinyl group Chemical group 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562235191P | 2015-09-30 | 2015-09-30 | |
| US62/235,191 | 2015-09-30 | ||
| PCT/US2016/054657 WO2017059191A1 (en) | 2015-09-30 | 2016-09-30 | Heteroaryl derivatives as sepiapterin reductase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018529739A JP2018529739A (ja) | 2018-10-11 |
| JP2018529739A5 true JP2018529739A5 (enExample) | 2019-11-14 |
| JP6896715B2 JP6896715B2 (ja) | 2021-06-30 |
Family
ID=57133442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517345A Active JP6896715B2 (ja) | 2015-09-30 | 2016-09-30 | セピアプテリン還元酵素としてのヘテロアリール誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9963462B2 (enExample) |
| EP (1) | EP3356345B1 (enExample) |
| JP (1) | JP6896715B2 (enExample) |
| CA (1) | CA3038280A1 (enExample) |
| DK (1) | DK3356345T3 (enExample) |
| ES (1) | ES2969565T3 (enExample) |
| WO (1) | WO2017059191A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201804901WA (en) | 2015-12-22 | 2018-07-30 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| CA3066939A1 (en) | 2017-06-21 | 2018-12-27 | SHY Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| CN107312011A (zh) * | 2017-06-29 | 2017-11-03 | 上海药明康德新药开发有限公司 | 外消旋‑7‑叔丁氧基羰基‑1‑氧亚基‑2,7‑二氮杂螺壬烷‑4‑羧酸的合成方法 |
| CN107817307B (zh) * | 2017-11-01 | 2020-12-25 | 重庆华邦制药有限公司 | Hplc法分离测定帕司烟肼及其相关杂质的方法 |
| WO2019145174A1 (en) | 2018-01-23 | 2019-08-01 | Basf Se | Preparation of optionally substituted 5-substituted pyridine |
| CN111630033A (zh) | 2018-01-23 | 2020-09-04 | 巴斯夫欧洲公司 | 任选取代的二氢异喹啉的制备 |
| US11591312B2 (en) | 2018-01-23 | 2023-02-28 | Basf Se | Halogenation of pyridine derivatives |
| WO2019145177A1 (en) | 2018-01-23 | 2019-08-01 | Basf Se | Bromination of pyridine derivatives |
| WO2019175332A1 (en) | 2018-03-14 | 2019-09-19 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Bh4 pathway inhibition and use thereof for treating t-cell mediated autoimmune diseases or hypersensitivity |
| TWI803696B (zh) * | 2018-09-14 | 2023-06-01 | 日商橘生藥品工業股份有限公司 | 次黃嘌呤化合物 |
| WO2020104930A1 (en) * | 2018-11-20 | 2020-05-28 | Piramal Enterprises Limited | An improved asymmetric synthesis of azaspiro compounds |
| WO2020132071A1 (en) | 2018-12-19 | 2020-06-25 | Shy Therapeutics. Llc | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease |
| KR20220082804A (ko) * | 2019-07-17 | 2022-06-17 | 싸이토키네틱스, 인코포레이티드 | 심장 근섬유분절 억제제 경구 제제들 |
| JP7385467B2 (ja) * | 2019-12-26 | 2023-11-22 | キッセイ薬品工業株式会社 | ヒポキサンチン化合物 |
| JP2021123539A (ja) * | 2020-02-03 | 2021-08-30 | キッセイ薬品工業株式会社 | ピロロピリミジノン化合物 |
| EP4219500A4 (en) | 2020-04-14 | 2024-10-23 | Nissan Chemical Corporation | FUSED HETEROCYCLIC COMPOUND |
| CN111393366B (zh) * | 2020-06-05 | 2020-09-01 | 北京华氏开元医药科技有限公司 | 四氢异喹啉类衍生物、制备方法、药物组合物及应用 |
| EP4185381A4 (en) * | 2020-07-24 | 2024-08-21 | Inipharm, Inc. | Thiophene hsd17b13 inhibitors and uses thereof |
| CN114262322A (zh) * | 2020-09-16 | 2022-04-01 | 中国科学院上海有机化学研究所 | 一类细胞程序性坏死抑制剂及其制备方法和用途 |
| AU2021377248A1 (en) | 2020-11-13 | 2023-06-22 | Inipharm, Inc. | Dichlorophenol hsd17b13 inhibitors and uses thereof |
| CN113072420B (zh) * | 2021-02-23 | 2022-05-20 | 中山大学 | 一类2-芳基取代的偕二氟环丁烷类化合物及其制备方法 |
| CN116490498B (zh) * | 2021-03-19 | 2025-09-02 | 南京迈晟科技有限责任公司 | 嘧啶并环类化合物及其用于制备治疗疼痛、脊髓损伤药物中的用途 |
| JP7743829B2 (ja) * | 2021-11-05 | 2025-09-25 | 小野薬品工業株式会社 | Ｋｄｍ５阻害作用を有する化合物を含有する医薬組成物 |
| CA3246424A1 (en) | 2022-04-08 | 2023-10-12 | SHY Therapeutics LLC | Compounds interacting with proteins of the RAS superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| WO2024109788A1 (zh) * | 2022-11-23 | 2024-05-30 | 成都先导药物开发股份有限公司 | Parp7抑制剂及其制备方法和用途 |
| CN116496195A (zh) * | 2023-05-10 | 2023-07-28 | 南京优氟医药科技有限公司 | 一种（r）-4,4-二氟代吡咯烷-2-羧酸的制备方法 |
| WO2025006293A2 (en) * | 2023-06-26 | 2025-01-02 | Merck Sharp & Dohme Llc | Inhibitors of human respiratory syncytial virus and metapneumovirus |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3040047A (en) | 1960-04-04 | 1962-06-19 | Takeda Pharmaceutical | 2-(pyrazol-1-yl)-pyrimidine derivatives |
| JPH04182636A (ja) | 1990-11-19 | 1992-06-30 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料 |
| JP2534423B2 (ja) | 1991-12-26 | 1996-09-18 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | 酸化窒素の過剰生産から生じる血管失調を阻止する阻害剤 |
| JPH05341428A (ja) | 1992-06-10 | 1993-12-24 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料 |
| TW312694B (enExample) | 1994-09-26 | 1997-08-11 | Daiichi Seiyaku Co | |
| CA2373510A1 (en) | 1999-05-12 | 2000-11-23 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazole carboxamides useful for the treatment of obesity and other disorders |
| WO2003037274A2 (en) * | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
| KR100929513B1 (ko) * | 2001-12-13 | 2009-12-03 | 아스비오파마 가부시키가이샤 | Ｐｄｅ７ 저해 작용을 갖는 피라졸로피리미디논 유도체 |
| GB2388594A (en) * | 2002-05-16 | 2003-11-19 | Bayer Ag | Imidazo-triazine PDE 4 inhibitors |
| TW200407143A (en) | 2002-05-21 | 2004-05-16 | Bristol Myers Squibb Co | Pyrrolotriazinone compounds and their use to treat diseases |
| US6933386B2 (en) | 2002-07-19 | 2005-08-23 | Bristol Myers Squibb Company | Process for preparing certain pyrrolotriazine compounds |
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| ATE440825T1 (de) | 2003-06-06 | 2009-09-15 | Vertex Pharma | Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern |
| NZ544756A (en) | 2003-07-22 | 2009-09-25 | Astex Therapeutics Ltd | 3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
| EP1696877A4 (en) | 2003-11-13 | 2010-06-09 | Gen Hospital Corp | PROCESS FOR PAIN TREATMENT |
| DE102004003428A1 (de) | 2004-01-23 | 2005-08-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Beta-2-Agonisten, und deren Verwendung als Arzneimittel |
| US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| AU2005288858B2 (en) | 2004-09-30 | 2011-04-21 | Janssen R&D Ireland | HCV inhibiting bi-cyclic pyrimidines |
| BRPI0608411A2 (pt) | 2005-03-10 | 2009-12-29 | Basf Ag | uso de um composto, composto, processo para preparar compostos, agente, semente, e, processo para combater fungos nocivos fitopatogênicos |
| US7534882B2 (en) | 2005-04-06 | 2009-05-19 | Bristol-Myers Squibb Company | Method for preparing pyrrolotriazine compounds via in situ amination of pyrroles |
| EP1921067A1 (en) | 2006-11-08 | 2008-05-14 | Bayer Schering Pharma Aktiengesellschaft | Indole and indazole derivatives as anti-inflammatory agents |
| WO2008055709A1 (en) | 2006-11-08 | 2008-05-15 | Bayer Schering Pharma Aktiengesellschaft | Indazole and indole derivatives as anti -inflammatory agents |
| WO2008092861A1 (en) | 2007-01-30 | 2008-08-07 | Janssen Pharmaceutica N.V. | Bicyclic derivatives as ep4 agonists |
| ATE542799T1 (de) | 2007-03-08 | 2012-02-15 | Janssen Pharmaceutica Nv | Chinolinonderivate als parp und tank-inhibitoren |
| WO2008131050A1 (en) | 2007-04-18 | 2008-10-30 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US20110046137A1 (en) | 2007-05-10 | 2011-02-24 | Glaxo Group Limited | Pyrazole Derivatives as P2X7 Modulators |
| JP2010533736A (ja) * | 2007-07-19 | 2010-10-28 | ハー・ルンドベック・アクチエゼルスカベット | ５員複素環アミドおよび関連化合物 |
| EP2062889A1 (de) | 2007-11-22 | 2009-05-27 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verbindungen |
| ES2548250T3 (es) | 2009-02-10 | 2015-10-15 | Janssen Pharmaceutica, N.V. | Quinazolinonas como inhibidores de prolilhidroxilasa |
| US20120252791A1 (en) | 2009-09-17 | 2012-10-04 | Julian Blagg | Heterocyclic GTP Cyclohydrolase 1 Inhibitors For the Treatment of Pain |
| EP2488025A4 (en) * | 2009-10-15 | 2013-04-03 | Childrens Medical Center | SEPIAPTERIC INTREDUCTASE INHIBITION FOR PAIN TREATMENT |
| WO2011088045A1 (en) | 2010-01-12 | 2011-07-21 | Ambit Biosciences Corporation | Aurora kinase compounds and methods of their use |
| WO2011138142A1 (en) | 2010-05-07 | 2011-11-10 | Ecole Polytechnique Federale De Lausanne (Epfl) | Compositions and use of sulfasalazine |
| DK2822656T3 (en) * | 2012-03-07 | 2017-01-30 | Inst Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| JP6097820B2 (ja) | 2012-05-04 | 2017-03-15 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ピロロトリアジノン誘導体 |
| WO2014015523A1 (en) | 2012-07-27 | 2014-01-30 | Hutchison Medipharma Limited | Novel heteroaryl and heterocycle compounds, compositions and methods |
| AR097631A1 (es) * | 2013-09-16 | 2016-04-06 | Bayer Pharma AG | Trifluorometilpirimidinonas sustituidas con heterociclos y sus usos |
-
2016
- 2016-09-30 EP EP16781631.3A patent/EP3356345B1/en active Active
- 2016-09-30 DK DK16781631.3T patent/DK3356345T3/da active
- 2016-09-30 CA CA3038280A patent/CA3038280A1/en active Pending
- 2016-09-30 WO PCT/US2016/054657 patent/WO2017059191A1/en not_active Ceased
- 2016-09-30 US US15/282,000 patent/US9963462B2/en active Active
- 2016-09-30 ES ES16781631T patent/ES2969565T3/es active Active
- 2016-09-30 JP JP2018517345A patent/JP6896715B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018529739A5 (enExample) | ||
| JP2017511357A5 (enExample) | ||
| JP2019502763A5 (enExample) | ||
| JP2016515560A5 (enExample) | ||
| JP2015514808A5 (enExample) | ||
| JP2017509689A5 (enExample) | ||
| JP2013529196A5 (enExample) | ||
| JP2010526098A5 (enExample) | ||
| JP2019512505A5 (enExample) | ||
| JP2017517538A5 (enExample) | ||
| JP2016506960A5 (enExample) | ||
| RU2017111200A (ru) | Циклогексилэтилзамещенные диаза- и триаза-трициклические соединения в качестве антагонистов индоламин-2,3-диоксигеназы для лечения рака | |
| JP2018524390A5 (enExample) | ||
| JP2015503625A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2018529650A5 (enExample) | ||
| JP2016506961A5 (enExample) | ||
| JP2016525135A5 (enExample) | ||
| JP2015531366A5 (enExample) | ||
| JP2016540742A5 (enExample) | ||
| JP2010522194A5 (enExample) | ||
| JP2017517512A5 (enExample) | ||
| JP2016523974A5 (enExample) | ||
| JP2014510147A5 (enExample) | ||
| JP2020511547A5 (enExample) |